Sangel Venture Capital

Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.

BioTroy Therapeutics is engaged in tumor immunity and is used for multi-omics tumor analysis, receptor-ligand discovery, research on target signal transduction pathways, antibody discovery and engineering, drug efficacy and large animal translational medicine, biomarkers, and precision medicine.

Yiyao Technology is a drug development company with throughput screening, CADD to data, and AI-driven strategies that possess the premise of intelligence.

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Aucta Pharmaceuticals is a drug development and commercialization company that leverages the 505(b)(2) regulatory pathway to create improved products from proven molecules. It develops and commercializes branded specialty products and technology platform-based niche generics, focusing on patient-centric innovations through new dosage forms, dosing regimens, and indications. The company concentrates on central nervous system disorders, ophthalmology, and inhalation therapies, aiming to bring better versions of proven molecules to market. Its platform enables the creation of novel and niche generic products, including formulations for poorly water-soluble compounds with controlled release, supporting development in CNS and oncology areas.

Ascentawits Pharmaceuticals Ltd. is a biotechnology company founded in 2014 and headquartered in Shenzhen, China. The firm specializes in the development of anti-tumor drugs, particularly focusing on small molecule targeted conjugated therapies. Ascentawits employs innovative drug design and screening techniques that leverage specific tumor micro-environments to create effective treatments for cancer patients. Through its research and development efforts, the company aims to improve therapeutic options for individuals battling various forms of cancer.

Denovo Biopharma (Hangzhou) Co. Ltd, based in Hangzhou, China, is a privately held biotechnology company specializing in biopharmaceuticals. The company focuses on personalized drug development through a unique platform that enables de novo genomic biomarker discovery using archived clinical samples. This innovative technology is particularly beneficial for late-stage clinical drugs that have previously demonstrated unsatisfactory efficacy. By identifying biomarkers linked to patient responsiveness, Denovo Biopharma assists biotech and pharmaceutical companies in designing targeted clinical trials, which aim to enhance efficacy and reduce adverse effects. Their biomarker discovery capabilities extend across various therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

3D Medicines is a biopharmaceutical company focused on developing personalized oncology therapies tailored to individual genetic backgrounds, aiming to enhance efficacy and safety for cancer patients.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Sidi Diagnostics is a medical technology company that focuses on new molecular diagnostic technologies.

Denovo Biopharma (Hangzhou) Co. Ltd, based in Hangzhou, China, is a privately held biotechnology company specializing in biopharmaceuticals. The company focuses on personalized drug development through a unique platform that enables de novo genomic biomarker discovery using archived clinical samples. This innovative technology is particularly beneficial for late-stage clinical drugs that have previously demonstrated unsatisfactory efficacy. By identifying biomarkers linked to patient responsiveness, Denovo Biopharma assists biotech and pharmaceutical companies in designing targeted clinical trials, which aim to enhance efficacy and reduce adverse effects. Their biomarker discovery capabilities extend across various therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology.

Shenzhen BrainNow Medical Technology Co., Ltd. specializes in cloud-based computing systems for medical imaging, focusing on quantitative and computational analysis. The company offers solutions such as AccuBrain, an automatic neuroimaging analysis system that aids clinicians in diagnosing neurological conditions. Additionally, it provides a cloud computing tool for the quantitative analysis of brain MR images, facilitating tasks like brain tissue segmentation, automatic quantification of brain lesions, and the detection of abnormal brain tissue. Founded in 2015 and located in Shenzhen, China, BrainNow serves a diverse clientele, including hospitals, physical examination centers, remote diagnostic platforms, and medical educational institutions. The company's technology enhances the identification and analysis of neuroimaging, supporting early screening and differential diagnosis of neurodegenerative diseases while improving clinical diagnostic accuracy and efficiency.

Magpie Pharmaceuticals is a biopharmaceutical company specializing in the research and development of innovative therapeutics aimed at treating various diseases, including cardiovascular, cerebrovascular, and central nervous system disorders. The company is dedicated to creating first-in-class drugs through the structural modification and transformation of active natural product monomers derived from traditional Chinese medicines, as well as small molecular compounds that are currently in clinical use. Magpie's therapeutic focus encompasses a range of conditions, including stroke, diabetic nephropathy, Parkinson's disease, dementia, glaucoma, and myocardial ischemia, with the goal of providing effective treatment options for patients suffering from these ailments.

Predicine Huidu Medical Technology Co., Ltd., based in Fengxian, China, specializes in the research and development of technologies for cancer diagnosis and monitoring. The company focuses on developing gene detection methods and bioinformatics algorithms, which enable healthcare companies to enhance tumor diagnosis and treatment. By connecting patients and healthcare providers through its clinical application platform, Predicine Huidu Medical Technology aims to advance the field of oncology and improve patient outcomes.

Quantapore Inc. is a biotechnology company based in Menlo Park, California, founded in 2009 by Sascha C. Dennstedt and Martin Huber. The company specializes in developing an innovative nanopore-based nucleic acid sequencing technology that utilizes an optical readout mechanism. This approach differentiates Quantapore from traditional nanopore methods by offering lower costs and higher throughput through quantum-optic interactions between optically labeled nanopores and nucleic acid samples. This technology enables rapid and sensitive single-molecule sequencing of entire genomes, significantly advancing the capabilities of genomic analysis and providing valuable tools for medical professionals to enhance human health.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

KBP is a leading biotechnology company focused on developing innovative therapies for unmet medical needs in areas such as cardiovascular, respiratory, inflammatory, and autoimmune diseases. It leverages a proprietary compound library and expertise in organ-specific disease models to deliver advanced therapeutic innovations.

CosBeauty is a company dedicated to skin health through the development of medical-grade home health consumer products. With a focus on transforming scientific research into effective consumer solutions, it offers a diverse range of products designed to enhance skin health. Serving over 2 million consumers across various regions, including China, Europe, America, Asia Pacific, and the Middle East, CosBeauty emphasizes precision and professionalism in its offerings. The company collaborates with the COSBEAUTY Institute of Precision Medicine, which unites experts from fields such as biomedicine, medical engineering, and artificial intelligence. This collaboration fosters a robust research and development framework that integrates life sciences, applied physics, and big data to create innovative beauty and personal care products, including advanced electronics for hair removal and skin rejuvenation.

Landing Shares is an AI-driven med-tech firm that develops artificial intelligence cervical cancer screening diagnostic technology.

EZlife Bio is a company that specializes in electric field-induced release and detection technology, known as EFIRM, which enables accurate genetic testing without the need for sample extraction or PCR. The EFIRM platform is designed to facilitate rapid and durable testing through the use of electrochemical biosensors. EZlife Bio offers a variety of services, including health monitoring, disease screening, non-invasive detection, pathogen analysis, and lifestyle and beauty assessments. The company focuses on precision detection technology for tumors and cancer, providing essential testing services such as early diagnosis, efficacy monitoring, and targeted drug resistance testing. Its product line includes detection software, liquid biopsy kits, and electrochemical molecular hybridization equipment, contributing to advancements in life science research and global health initiatives.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.

Beijing Baolaitong Technology Co., Ltd., established in 2010 and headquartered in Beijing, China, specializes in providing internet technology services tailored to the medical industry. The company focuses on developing solutions for the pharmaceutical sector, including a distribution management system for off-hospital settings and an integrated patient assistance system. These offerings enable hospitals to efficiently manage various aspects of medical treatment, including medication distribution and patient payments, thereby enhancing operational effectiveness in healthcare delivery.

Science For Life offers telemedicine solutions and services. They work on product development, program design, project construction, technical support, and service operations in the field of telemedicine. Their solutions include two way referral, post-hospital follow-up, remote monitoring, mobile medical, and teleconsultation.

Green Path Technology is a design and research company. It provides product quality, environmental protection regulation research, and ecological management system development solutions. Their services include consultation, substance information identification, quality and environmental solutions, and SDS production. They serve the manufacturing industry.

MAXCOM is engaged in research and development, manufacture, and sales of hematology.